Chicago Capital LLC Has $6.74 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Chicago Capital LLC trimmed its position in Edwards Lifesciences Co. (NYSE:EW) by 29.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,171 shares of the medical research company’s stock after selling 42,395 shares during the quarter. Chicago Capital LLC’s holdings in Edwards Lifesciences were worth $6,742,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in EW. Park Avenue Securities LLC raised its position in shares of Edwards Lifesciences by 0.5% in the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock valued at $2,169,000 after buying an additional 108 shares in the last quarter. City State Bank raised its holdings in Edwards Lifesciences by 16.5% in the 2nd quarter. City State Bank now owns 917 shares of the medical research company’s stock valued at $85,000 after acquiring an additional 130 shares in the last quarter. Chapin Davis Inc. lifted its position in shares of Edwards Lifesciences by 1.7% during the 1st quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock valued at $817,000 after acquiring an additional 140 shares during the period. Valley National Advisers Inc. grew its holdings in shares of Edwards Lifesciences by 6.0% during the 1st quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock worth $255,000 after purchasing an additional 152 shares in the last quarter. Finally, Choreo LLC increased its position in shares of Edwards Lifesciences by 4.1% in the first quarter. Choreo LLC now owns 3,840 shares of the medical research company’s stock worth $367,000 after purchasing an additional 153 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares in the company, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares in the company, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total transaction of $333,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,133,916.72. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,250 shares of company stock valued at $1,099,238 in the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Citigroup cut their price objective on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday, October 1st. Barclays cut their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 11th. Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Finally, Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their target price for the company from $85.00 to $70.00 in a report on Wednesday, September 18th. Fifteen analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $75.81.

Edwards Lifesciences Trading Up 2.6 %

Shares of EW stock opened at $70.27 on Friday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The stock has a 50 day simple moving average of $67.81 and a two-hundred day simple moving average of $79.18. The company has a market cap of $42.34 billion, a P/E ratio of 30.29, a PEG ratio of 2.83 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. The company had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. Edwards Lifesciences’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.66 EPS. Research analysts forecast that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.